With multiple ADCs now available for use in gynecologic cancers, treatment decision-making incorporates biomarker nuances and raises sequencing questions.
|Videos|May 5, 2011
Dr. Karlan Discusses AMG 386 in Recurrent Ovarian Cancer
Author(s)Beth Y. Karlan MD
Beth Y. Karlan MD Discusses AMG 386 in Recurrent Ovarian Cancer
Advertisement
Beth Y. Karlan MD, a Director at Cedars-Sinai Women's Cancer Research Institute Discusses AMG 386 in Recurrent Ovarian Cancer
Advertisement
Related to this article
Advertisement
Advertisement
Trending on OncLive
1
Dr Cercek on the FDA Approval of Dostarlimab for dMMR/MSI-H Locally Advanced Rectal Cancer
2
Vilamakitug Meets OS Threshold in Phase 1/2 Refractory mCRC Trial
3
Weigh Benefit Against Burden: Defining Lurbinectedin’s Role in a Shifting Small Cell Lung Cancer Landscape
4
Dr Warren on the Goal of the 4WARD Trial Evaluating Mavorixafor in Chronic Neutropenia
5